Mianserin’in sıçanlarda streptozotosin ile indüklenen hiperglisemi ve metabolik değişiklikler üzerine etkisi

Abstract

AbstractÖz Purpose: The aim of this study was to investigate possible effects of atypical antidepressant mianserin on glycemia levels and metabolic parameters of normoglycemic and diabetic rats. Material and Methods: Effects of mianserin administration on blood glucose levels in rats were assessed by measuring "fasting blood glucose", "glycosylated haemoglobin" levels and conducting the "oral glucose tolerance test". Changes in metabolic parameters such as food and water consumption and urine and faeces excretion were observed using metabolic cages. Results: Administration of mianserin for 7 and 14 days at doses of 30 and 45 mg/kg significantly reduced the hyperglycemia and elevated HbA1c levels; also improved hyperglycemia induced polydipsia, polyuria, polyphagia, and increased faeces amounts. Mianserin, at both of the administrated doses, reduced the weight loss observed in diabetic animals. With regard to the anti-hyperglycaemic effect, mianserin administered at a dose of 30 mg/kg was found to be as effective as the reference drug metformin (dose, 1 g/kg). Conclusion: This study showed that the antihyperglycemic effect of mianserin, an atypical antidepressant, was comparable to those of the reference drug metformin. However, the pharmacological mechanisms underlying this anti-hyperglycemic effect of mianserin remain to be elucidated.

Mirtazapine Reduces Adipocyte Hypertrophy and Increases Glucose Transporter Expression in Obese Mice

“…Our findings regarding long-term mirtazapine use indicate mirtazapine's potential to enhance glucose homeostasis and thus reduce glucose intolerance and IR risk, potentially followed by alleviation of hyperglycemia. Along with previous findings [57,58,60], these results indicate that mirtazapine treatment, particularly long-term treatment, can have beneficial effects on glucose homeostasis, such as reducing glucose levels and improving IS, in animals with DM. However, other clinical studies have reported that mirtazapine-treated animals experienced weight gain [42,61].…”

“…This may be caused by reductions in hyperglycemia, as demonstrated by the alleviation of glucose intolerance in an IPGTT. Studies have found that treatment with mirtazapine and mianserin (a mirtazapine analog) in rats with type 1 DM can reduce blood glucose levels [57,58]. These findings suggest that mirtazapine affects IS by attenuating long-term HFD consumption-induced hypoglycemia because increased insulin signaling reverses the exacerbated metabolic state to ensure glucose homeostasis maintenance.…”